Sherman and Howard Client Ortho Agency Awarded Landmark Jury Verdict in Corporate‑Raiding Case

Medical-Device Distributor Wins Against Exactech and Former Sales Director for Takeover of Business Relationships, Misusing Trade Secrets and Poaching Contracted Sales Representatives

Sherman and Howard announced a recent jury verdict in favor of its clients Michael Shatzer and The Ortho Agency LLC against its former sales director, Chad Giarratano, and global medical device manufacturer Exactech U.S., Inc., for allegedly collaborating to take over existing and prospective business relationships, violating contractual agreements with Ortho Agency, misusing Ortho Agency’s trade secrets, and poaching contracted sales representatives. Mr. Shatzer and Ortho Agency were represented by trial lawyers Peter G. Koclanes and Nick M. DeWeese.

Sherman and Howard  said after a five-day trial in Denver District Court, a jury found in favor of Mr. Shatzer and Ortho Agency on all of their claims, including that Exactech had breached an exclusive Sales Agency Agreement to sell its products to hospitals, surgeons and surgery centers in three states and portions of two others. The jury further found that Mr. Giarratano and his business entities had breached their Independent Services Agreement based upon the Defendants conducting a months-long stealth campaign to eliminate Mr. Shatzer and Ortho Agency as the exclusive distributor for Exactech in those territories and to take over their business. The jury awarded Mr. Shatzer and Ortho Agency $4,000,001.

“This jury verdict is a landmark decision in the medical-device industry where corporate raiding of smaller distributors’ business and personnel by large manufacturers occurs all too often,” said Peter G. Koclanes. “Given the dollar amount ordered by the jury, its verdict is one of the largest monetary awards for damages for a case of this kind in Colorado in the last several years.”

In addition to alleging that Exactech breached its Sales Agency Agreement, Ortho Agency alleged that Mr. Giarratano breached his contractor agreement with the company in a variety of ways, including violating non-disclosure of confidential and trade secret information, non‑competition, and non-solicitation provisions, including when he went to work for Exactech as a new distributor, and solicited and recruited Ortho Agency’s sales personnel to work for his distributorship and Exactech.

“This is a defining verdict in the medical-device industry and sends a clear message that manufacturers in this field should not engage in conduct that interferes with their distributors’ sales and customer relationships, or with the distributors’ relationships with their sales representatives,” said Nick M. DeWeese.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version